Full-Time

Specialist

LNP Process Development

Confirmed live in the last 24 hours

Moderna

Moderna

5,001-10,000 employees

Develops mRNA-based medicines for health

Biotechnology
Healthcare

Mid

Norwood, MA, USA

70% in-office work model.

Category
Computational Biology
Biology Lab & Research
Biology & Biotech
Required Skills
Power BI
Microsoft Azure
Python
Data Science
Apache Spark
SQL
Tableau
AWS
Requirements
  • Bachelor’s degree in Computer Science, Software Engineering or a related field.
  • 3+ years of experience in data science, analytics and mining with certification in cloud technologies.
  • Proficiency in SQL, Python, and data pipeline tools (e.g., Apache Spark).
  • Experience with cloud platforms (AWS, Azure) and big data technologies.
  • Strong problem-solving skills and attention to detail.
  • Ensure data quality, integrity, and security across systems.
  • Implement best practices for excising or developing data governance and management.
  • Proficiency in statistical analysis, machine learning, and data visualization.
  • Knowledge of data governance best practices.
  • Familiarity with FDA guidance and relevant CFR compliance requirements.
  • Experience with machine learning pipelines and model deployment.
  • Knowledge of data visualization tools like Tableau or Power BI.
Responsibilities
  • Develop and maintain data pipelines to support LNP process development, delivery and process chemistry, specifically, but not limited to, small molecules.
  • Collaborate with process engineers and scientists to collect, analyze, and visualize data according to Moderna data governance initiatives.
  • Optimize data storage solutions for high-volume experimental data, in accordance with Moderna data governance across Technical Development, Digital, Research and Development, and Quantitative Sciences.
  • Create dashboards and reporting tools to visualize process metrics and outcomes.
  • Collaborate with scientist to interrogate inputs in data warehouses against external sources in the literature to inform risk assessments and de-risk overall upstream process robustness.

Moderna focuses on developing medicines using messenger RNA (mRNA), which is a molecule that provides instructions for cells to produce proteins essential for various biological functions. Their approach involves creating a new class of medicines that leverage mRNA to potentially enhance the discovery, development, and manufacturing of drugs. Unlike traditional methods, which often rely on proteins or other biological materials, Moderna's use of mRNA allows for a more direct and efficient way to instruct cells to produce therapeutic proteins. The company's goal is to improve patient outcomes by harnessing the power of mRNA technology to create effective treatments for a range of diseases.

Company Stage

IPO

Total Funding

$5.9B

Headquarters

Cambridge, Massachusetts

Founded

2010

Growth & Insights
Headcount

6 month growth

3%

1 year growth

15%

2 year growth

53%
Simplify Jobs

Simplify's Take

What believers are saying

  • Moderna's new plant in Shanghai expands its manufacturing and market presence in Asia.
  • The Victoria vaccine facility enhances Moderna's global production capacity.
  • Collaboration with OpenAI may enhance drug discovery and development processes.

What critics are saying

  • Legal challenges over mRNA technology could impact financial stability.
  • Hong Kong residents' vaccine reticence may affect market penetration.

What makes Moderna unique

  • Moderna is pioneering mRNA as a new class of medicines.
  • The company has developed one of the earliest effective COVID-19 vaccines.
  • Moderna's mRNA platform targets infectious, rare, and autoimmune diseases.

Help us improve and share your feedback! Did you find this helpful?